Wednesday, September 23, 2026. 12 PM-1 PM ET
Roundtable presenters Dr. David Sacks MB, ChB, FRCPath, Chairman, Steering Committee National Glycohemoglobin Standardization Program (NGSP), and Priya Sivaraman, PhD, Senior Technical Product Manager, Tosoh Bioscience
Moderated by: Bob McGonnagle, Publisher, CAP TODAY
Thursday, September 24, 2026 11 AM-12 PM CT
This session explores the evolving role of RAS in precision oncology, from the biology of RAS mutations to the expanding landscape of targeted therapies. Through expert presentations, real-world case discussions, and interactive audience polling, participants will examine best practices for RAS biomarker testing across solid tumors, including lung, colorectal, and pancreatic cancers. The session will highlight practical considerations for tissue and liquid biopsy, strategies to address testing gaps, and the importance of multidisciplinary collaboration to ensure timely identification of patients who may benefit from RAS-targeted therapies.
Webinar presenters David Braxton, MD, Chief of Molecular Pathology Services, Hoag Family Cancer Institute & Hoag Memorial Hospital Presbyterian, and Carlos Becerra, MD, Research Director for Medical Oncology, Margaret Given Larkin Endowed Chair for Developmental Cancer Therapeutics, Hoag Memorial Hospital Presbyterian
Moderated by: Bob McGonnagle, Publisher, CAP TODAY
Wednesday, September 30, 2026. 1 PM-1:30 PM ET
Roundtable presenters John Longshore, PhD, Head of Scientific Affairs, Global Oncology Diagnostics, AstraZeneca, and Flora Berisha, MS, Executive Director, Global Head of Diagnostic Partnering and Development, Johnson & Johnson Innovative Medicine, and Mark D. Ewalt, MD, Associate Medical Director for Laboratory Operations, Diagnostic Molecular Pathology, Molecular Diagnostics Service, Department of Pathology and Laboratory Medicine, Memorial Sloan Kettering Cancer Center, and Isabel Preeshagul, DO, MBS, Thoracic Medical Oncologist, Memorial Sloan Kettering Cancer Center
Moderated by: Bob McGonnagle, Publisher, CAP TODAY
Thursday, October 1, 2026 1 PM-2 PM ET
This presentation will explore the value of in-house CGP, offer insights into the benefits and drawbacks of incorporation, and provide information about important practical factors when considering in-house implementation of CGP.
Webinar presenter Allison M. Cushman-Vokoun, MD, PhD, FCAP, Medical Director, Molecular Diagnostics and Personalized Medicine Laboratory, Director, Division of Diagnostic Molecular Pathology and Human Genetics, Henry F. Krous Professor of Pathology, University of Nebraska Medical Center
Moderated by: Bob McGonnagle, Publisher, CAP TODAY
Tuesday, October 20, 2026 11 AM-12 PM ET
Hear experts review the biological and clinical significance of the HER2 expression continuum in breast tissue, providing a clearer understanding of how these variations might impact diagnosis, and discuss the emerging importance of documenting HER2-low and HER2-ultralow categories using a validated IHC assay.
Webinar presenters Keith Wharton, MD, PhD, Global Medical Affairs Leader–Pathology, Roche Diagnostics Solutions, and Hannah Y. Wen, MD, PhD, Director, Breast Pathology Fellowship, Associate Team Leader, Breast Pathology Team, Attending Pathologist, Memorial Sloan Kettering Cancer Center
Moderated by: Bob McGonnagle, Publisher, CAP TODAY
January 2015—Thermo Fisher Scientific launched its DRI Hydrocodone/Hydromorphone Assay, a homogeneous enzyme immunoassay that specifically detects hydrocodone and major metabolites in human urine at a 300 ng/mL cut-off. The assay uses liquid ready-to-use reagents, calibrators, and controls and can be run in qualitative and semiquantitative modes.
January 2015—Leica Biosystems has completed its acquisition of Devicor Medical Products. The Cincinnati-based company has annual revenues of approximately $170 million and more than 550 employees.
January 2015—Chembio Diagnostics announced it has entered into an exclusive agreement with Integrated BioTherapeutics, a biotechnology company focused on the discovery of novel vaccines and therapeutics for emerging infectious diseases. Under the terms of the agreement, Chembio will combine its patented Dual Path Platform technology with IBT’s proprietary Ebola reagents to develop POC diagnostic tests for Ebola and febrile illness. Chembio will have exclusive rights to any POC product developed through this agreement.
January 2015—Beckman Coulter Diagnostics has launched its next-generation Hemoglobin A1c assay with improved performance across its chemistry systems. The assay has been standardized for use on all platforms of the company’s AU clinical chemistry systems for off-line sample preparation use and for online sample preparation use on the company’s UniCel DxC systems and is FDA 510(k) cleared for both analyzers.
January 2015—Empirical Bioscience, formerly known as Syzygy Biotech, has introduced FlashTaq Hot-Start Taq DNA Polymerase, a chemically modified Taq polymerase designed to reduce nonspecific amplification in PCR.
January 2015—Cornerstone Medical and Technology Finance specializes in assisting small medical practice owners obtain capital. Cornerstone can customize financing programs for pathologists who would like to remodel, expand, or relocate their office or to purchase additional equipment.
January 2015—Biocare Medical has been awarded a U.S. patent for its anti-PAX8 mouse monoclonal antibody, clone [BC12]. The PAX8 antibody [BC12] is designed to target a restricted epitope and exhibits higher specificity and provides sharper staining than the PAX8 rabbit polyclonal antibody.
January 2015—Qiagen will offer global distribution of the RealStar Ebolavirus RT-PCR Kit 1.0. The diagnostic kit, developed and manufactured by Altona Diagnostics, is a reverse transcription polymerase chain reaction test intended for the qualitative detection of RNA from all known strains of Ebola viruses. Qiagen will distribute the kit and Altona’s already CE-IVD marked test, the RealStar Filovirus RT-PCR Kit, which is for both Ebola and Marburg viruses and does not fall under the emergency use authorization.
Search our marketplace index for pathology lab products and industry news from dozens of companies.
December 2014—Advanced Cell Diagnostics has been awarded a two-year, $1.4 million grant from the National Cancer Institute under its Small Business Innovation Research Grant phase two program. ACD and its academic partner, Cleveland Clinic, will use the grant to develop and validate a diagnostic test based on ACD’s proprietary RNAscope technology for discriminating various B-cell non-Hodgkin lymphomas from benign lymphoproliferative diseases.
